| Autor: |
Tanaka, Masahisa, Azuno, Yoichi, Yoshizaki, Yoshiki, Hatao, Katsuhiro, Fujii, Yasuhiko, Okubo, Masashi, Inoue, Yasushi, Matsutani, Akira, Yaga, Ken, Fujii, Shinya, Ishida, Yoji, Kaku, Kohei, Matsumura, Shigeichi, Kaneko, Toshio, Shinohara, Kenji, Hiroshige, Yukio, Matsumoto, Noboru |
| Jazyk: |
angličtina |
| Rok vydání: |
1989 |
| Předmět: |
|
| Zdroj: |
山口医科大学紀要. 36(1-2):21-27 |
| Popis: |
Combination chemotherapy with CHOP-Pepleo regimen (cyclophosphamide, adriamycin, vincristine, prednisolone, and pepleomycin), or COP-Pepleo refimen (cyclophosphamide, vincristine, prednisolone, and pepleomycin), was used as a remission induction therapy for patients with mostly advanced non-Hodgkin's lymphomas. Among 23 patients treated with CHOP-Pepleo or CHOP without Pepleo (5 patients), 57% achieved complete remission with 78% overall response (complete remission plus partisl remission). Among 12 patients treated with COP-Pepleo, 50% achieved complete remissions with 83% overall response. No significant difference was odserved in response rates between two groups. Median follow-up durations ware 14 months for CHOP-People and 16 months for COP-Pepleo and 4 patients (67%) treated with COP-Pepleo relapsed within 20 months after achieving complete remission. Relapse-free survival rates at 4 years ware 54% for CHOP-Pepleo and 34% for COP-Pepleo. Each survival curve in the patients treated with CHOP-Pepleo or COP-Pepleo showed a plateau after 24 months. Though the addition of adriamycin did not improve complete remission rate significantly as a whole, the complete remission rate in stage Ⅳ , overall survival and relapse-free survival ware favorably inproved by the addition of adriamycin. Further study will be needed to assess the effect of adriamycin on response and survival in patients eith non-Hodgkin's lymphomas. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
